This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Otsuka Holdings Co., Ltd.
Drug Names(s): decitabine, E7373
Description: Dacogen (decitabine) is a cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication.
MGI Pharma and SuperGen
Under the terms of a September 2004 agreement, MGI Pharma will make a $40 million equity investment in SuperGen at $10.00 per share and will pay SuperGen up to $45 million based upon achievement of specified regulatory and commercialization milestones. SuperGen will continue with its filing of the MDS applications for regulatory approval in the U.S. and Europe with assistance from MGI Pharma. SuperGen will receive a royalty on worldwide net sales starting at 20% and escalating to a maximum of 30%. MGI Pharma has also committed to fund further development costs associated with Dacogen, at a minimum of $15 million.
MGI Pharma and Cilag
In July 2006, MGI Pharma signed a license agreement with Cilag GmbH, a Johnson & Johnson (JNJ) company, granting exclusive development and commercialization rights for Dacogen in all territories outside North America to Janssen-Cilag companies. Under the terms of this agreement, MGI Pharma will retain...See full deal structure in Biomedtracker
Partners: Johnson & Johnson Eisai Co., Ltd.
Pink Sheet Eisai To Try New Dosing sNDA For Dacogen
Additional information available to subscribers only: